Company Filing History:
Years Active: 2020
Title: Innovations in Cancer Treatment: The Contributions of Jianing Xu
Introduction
Jianing Xu is an accomplished inventor based in the Bronx, NY. She has made significant contributions to the field of cancer research, particularly in the development of biomarkers for evaluating the effectiveness of rapamycin analogs in cancer treatment. Her innovative work aims to improve therapeutic outcomes for patients suffering from kidney cancer.
Latest Patents
Jianing Xu holds a patent titled "Biomarkers for response to rapamycin analogs." This invention focuses on the use of specific biomarkers to assess the likelihood that a rapamycin analog will produce an anti-cancer effect in a subject. The patent is based on experiments that utilized an integrated next-generation sequencing approach to analyze tumor specimens. These experiments revealed important insights into intra-tumor and intertumor heterogeneity, as well as the oncogenomic factors that contribute to the therapeutic benefits of rapalogs in kidney cancer patients. The invention provides assay methods and kits for detecting loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function mutations in mTOR, which are crucial for selecting appropriate therapeutic regimens for cancer patients.
Career Highlights
Jianing Xu is affiliated with the Memorial Sloan Kettering Cancer Center, where she continues her research and development efforts. Her work has the potential to significantly impact the treatment landscape for cancer patients, particularly those with specific genetic backgrounds that influence their response to therapies.
Collaborations
Jianing has collaborated with notable colleagues, including James Hsieh and Michael Berger. These partnerships have further enhanced her research capabilities and contributed to the advancement of cancer treatment methodologies.
Conclusion
Jianing Xu's innovative work in identifying biomarkers for cancer treatment exemplifies the critical role of research and invention in improving patient outcomes. Her contributions are paving the way for more personalized and effective cancer therapies.